Abstract:Objective: To evaluate the safety and efficacy of chimeric antigen receptors T cells (CAR-T) in childhood acute B lymphoblastic leukemia (B-ALL) to probe the prognosis-related factors. Methods: Forty-eight children, 29 boys and 19 girls, aged 3-17years old (median age was 8 years old) , with recurrent or refractory CD19 positive B-ALL, were treated by the CD19 specific CAR-T cells. A total of 48 cases received 61 infusions. Flow cytometry or real-time quantitative polymerase chain reaction method were used to monitor micro residual disease (MRD) . The follow-up period was from 16 to 1 259 days with the median follow-up of 406 days. SPSS software was used to statistical analysis. Results: No adverse reaction was observed during 61 infusions. The most common adverse reaction after CAR-T cell infusions was cytokine-release syndrome (CRS) . Only 2 cases experienced level 3 CRS performance, including continuous high fever, convulsions, delirium, serous cavity effusion, and decreasing of blood pressure. Tocilizumab was given to release CRS performance. No treatment-related death occurred. Thirty-seven patients showed response during 7 to 28 days after infusions. The early response rate was 77.1%, with MRD before infusion less than 5% group higher than the MRD more than 5% group (87.1% vs 58.8%, χ2=4.968, P=0.036) . For the 37 patients who showed response to CAR-T cell infusions, univariate analysis identified that age, disease status at the time of treatment, MRD before infusion affected 2-year OS rate (P<0.05) . Multivariate prognostic analysis for EFS disclosed that the MRD before infusion more than 5% (RR=3.433, 95% CI 1.333-8.844, P=0.011) and not bridge to HSCT (RR=4.996, 95% CI 1.852-13.474, P=0.001) were the independent risk factors. Conclusion: The fourth generation CAR-T cells directed against CD19 could effectively and safely treat relapsed and refractory B-ALL, which implicated that CAR-T therapy as a novel therapeutic approach could be useful for patients with relapsed or refractory B-ALL who have failed all other treatment options. Reducing MRD as far as possible by effective pretreatment chemotherapy was in favor of increasing the response rate. Bridging HSCT after CAR-T cell treatment might be a better therapeutic strategy for the patient with refractory or molecular relapsed B-ALL.

[Recent Research on Chimeric Antigen Receptor T Cells in Children with Refractory/relapsed Acute Lymphoblastic Leukemia].

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

Advances of CD19-directed Chimeric Antigen Receptor-Modified T Cells in Refractory/relapsed Acute Lymphoblastic Leukemia

Cd19 Targeted Chimeric Antigen Receptor T (Car-T) Cell Immunotherapy Has Demonstrated Significant Anti-Leukemia Activity In Pediatric Patients With Relapsed/Refractory Acute Lymphocytic Leukemia: A Multicentre Study In China.

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

[Chimeric Antigen Receptors T Cells in Treatment of a Relapsed Pediatric Acute Lymphoblastic Leukemia, Relapse after Allogenetic Hematopoietic Stem Cell Transplantation: Case Report and Review of Literature Review].

Potent Anti-Leukemia Activities of Humanized CD19-targeted Chimeric Antigen Receptor T (CAR-T) Cells in Patients with Relapsed/refractory Acute Lymphoblastic Leukemia.

Recent Advances in Immunotherapy of Acute Leukemia Via Chimeric Antigen Receptor-Engineered T Cells

[Efficacy of Chimeric Antigen Receptor T Cell in the Treatment of Refractory/Recurrent B Acute Lymphocytic Leukemia in Children].

Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?

Recent advances in CAR T-cell therapy for lymphoma in China

Advances of CAR-T cell immunotherapeutic targeting for malignant tumors of children

Progress in clinical application of chimeric antigen receptor-T cells for the refractory and relapsed B-cell leukemia

[Chimeric Antigen Receptors T Cells for Treatment of 48 Relapsed or Refractory Acute Lymphoblastic Leukemia Children: Long Term Follow-Up Outcomes].

Advances in chimeric antigen receptor T cell therapy for treatment of hematological malignancies

Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope

Chimeric antigen receptor T cell immunotherapy for refractory and relapsed acute lymphoblastic leukemia: Challenge and Countermeasures

Research Progress of Chimeric Antigen Receptor Modified T Cells in Treatment of Acute Myeloid Leukemia

Chimeric Antigen Receptor T Cell Therapy for Acute Leukemia

Efficacy and Safety of Children with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia after Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience